IRIS
IANNONE, ROSA FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 200
NA - Nord America 129
AS - Asia 23
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 354
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 129
IE - Irlanda 85
SE - Svezia 54
UA - Ucraina 23
SG - Singapore 13
CZ - Repubblica Ceca 10
DE - Germania 9
IT - Italia 8
CN - Cina 7
FI - Finlandia 4
FR - Francia 3
GB - Regno Unito 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BD - Bangladesh 1
IN - India 1
IR - Iran 1
MD - Moldavia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
Totale 354
Salva come PNG Salva come JPEG
Città #
Dublin 85
Chandler 34
Nyköping 34
Ashburn 13
Jacksonville 13
Brno 10
Singapore 8
Princeton 7
Wilmington 7
Munich 6
Los Angeles 5
Helsinki 4
Beijing 3
Chicago 2
Foggia 2
Guiyang 2
New York 2
Nuremberg 2
Washington 2
Bari 1
Boardman 1
Changsha 1
Chisinau 1
Clearwater 1
Delhi 1
Hangzhou 1
Hanover 1
Köpingebro 1
London 1
Milan 1
Naples 1
Paris 1
Phoenix 1
Santa Venerina 1
Seattle 1
Tappahannock 1
Taranto 1
Wellingborough 1
Wellington 1
Totale 261
Salva come PNG Salva come JPEG
Nome #
Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis 52
What have multicentre registries across the world taught us about the disease features of systemic sclerosis? 51
ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis - A EUSTAR analysis 51
Preliminary data on post market safety profiles of covid 19 vaccines in rheumatic diseases: Assessments on various vaccines in use, different rheumatic disease subtypes, and immunosuppressive therapies: A two-centers study 47
Factors predicting early discontinuation of methotrexate as a first-line treatment for rheumatoid arthritis in Italy: Results from the GISEA registry 43
Thoracic lymphadenopathy as possible predictor of the onset of interstitial lung disease in systemic sclerosis patients without lung involvement at baseline visit: A retrospective analysis 38
Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA 35
Arthritis in Systemic Lupus Erythematosus: From 2022 International GISEA/OEG Symposium 25
Retention rate of a second line with a biologic DMARD after failure of a first-line therapy with abatacept, tocilizumab, or rituximab: results from the Italian GISEA registry 17
Racial differences in systemic sclerosis disease presentation: A European Scleroderma Trials and Research group study 15
Survival and prognostic factors from a multicentre large cohort of unselected Italian systemic sclerosis patients 14
Real-world effectiveness and persistence of golimumab as second-line anti-TNFα drug in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis patients in Italy: GO-BEYOND, a 12-month prospective observational study 9
Sex influence on outcomes of patients with systemic sclerosis-associated interstitial lung disease: A EUSTAR database analysis 5
Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research 4
Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database 4
Totale 410
Salva come PNG Salva come JPEG
Categoria #
all - tutte 3.638
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.638
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202013 0 0 0 0 0 2 4 0 5 0 2 0
2020/202149 2 3 5 0 5 1 7 11 7 7 1 0
2021/202260 0 1 0 0 7 1 0 6 11 24 0 10
2022/2023205 14 11 12 5 9 20 0 22 92 5 13 2
2023/202479 4 3 6 6 8 12 0 1 0 6 7 26
2024/20254 4 0 0 0 0 0 0 0 0 0 0 0
Totale 410